alexa Genetic Mutations and Humanized Monoclonal Antibody Tre

Journal of Lung Cancer Diagnosis & Treatment
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Genetic Mutations and Humanized Monoclonal Antibody Treatment in Small- Cell Lung Cancer: A Review

de Moraes Junior RM, Mota GS, Carolino MLO and Kerche-Silva LE*

Medical School of Presidente Prudente, Western Sao Paulo University, Brazil

*Corresponding Author:
Kerche-Silva LE
Medical School of Presidente Prudente
Western Sao Paulo University, Jose Bongiovani St
700, 19050-920, Presidente Prudente-SP, Brazil
Tel: +551832291000
E-mail: [email protected]

Received date: May 15, 2017; Accepted date: May 23, 2017; Published date: May 30, 2017

Citation: de Moraes JRM, Mota GS, Carolino MLO, Kerche-Silva LE (2017) Genetic Mutations and Humanized Monoclonal Antibody Treatment in Small-Cell Lung Cancer: A Review. J Lung Cancer Diagn Treat 2:115.

Copyright: © 2017 de Moraes, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Small-cell lung cancer (SCLC) is one of the deadliest type of cancer with fast tumor growth and rapid metastatic dissemination. The most common genetic modifications associated with SCLC is connected to tumor suppressor and oncogenic genes, genes that control the cycle arrest of the cells. Standard treatment for SCLC is a combination of drugs such as cisplatin and etoposide and sometimes radiotherapy of the chest can be used. But these treatments have not been sufficient to decrease dead rate in SCLC patients and new drugs have been studied, specially humanized monoclonal antibodies (mAb). Therefore, the aim of this work is to review the main genetic alterations in SCLC and the mAb that has been tested to improve life expectancy in these patients.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords